NCT04632927 - Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

October 22, 2024

Study Completion Date

October 22, 2024

Conditions

Psoriatic Arthritis

Interventions

BIOLOGICAL

Secukinumab

Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

BIOLOGICAL

Ustekinumab

Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

Trial Locations (28)

12435

Novartis Investigative Site, Berlin

13125

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

18209

Novartis Investigative Site, Bad Doberan

22391

Novartis Investigative Site, Hamburg

24768

Novartis Investigative Site, Rendsburg

35630

Novartis Investigative Site, Ehringshausen

37075

Novartis Investigative Site, Göttingen

39104

Novartis Investigative Site, Magdeburg

39110

Novartis Investigative Site, Magdeburg

39245

Novartis Investigative Site, Gommern

40878

Novartis Investigative Site, Ratingen

44649

Novartis Investigative Site, Herne

44791

Novartis Investigative Site, Bochum

48455

Novartis Investigative Site, Bad Bentheim

50937

Novartis Investigative Site, Cologne

51149

Novartis Investigative Site, Cologne

52074

Novartis Investigative Site, Aachen

55131

Novartis Investigative Site, Mainz

60590

Novartis Investigative Site, Frankfurt

79106

Novartis Investigative Site, Freiburg im Breisgau

81541

Novartis Investigative Site, München

82152

Novartis Investigative Site, Planegg

91056

Novartis Investigative Site, Erlangen

03042

Novartis Investigative Site, Cottbus

01067

Novartis Investigative Site, Dresden

01307

Novartis Investigative Site, Dresden

04103

Novartis Investigative Site, Leipzig